Literature DB >> 15795330

Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice.

Sabine Merl1, Cornelia Michaelis, Birgit Jaschke, Marc Vorpahl, Stefan Seidl, Rainer Wessely.   

Abstract

BACKGROUND: Enteroviridae such as coxsackievirus B3 (CVB3) are important infectious agents involved in viral heart disease, hepatitis, and pancreatitis, but no specific antiviral therapy is available. METHODS AND
RESULTS: The aim of the present study was to evaluate the impact of RNA interference on viral replication, cytopathogenicity, and survival. Small interfering RNA (siRNA) molecules were designed against the viral 2A region (siRNA-2A), which is considered to be highly conserved and essential for both virus maturation and host cytopathogenicity. siRNA-2A exhibited a significant protective effect on cell viability mediated by marked inhibition of CVB3 gene expression and viral replication. In highly susceptible type I interferon receptor-knockout mice, siRNA-2A led to significant reduction of viral tissue titers, attenuated tissue damage, and prolonged survival. Repeated siRNA-2A transfection was associated with a further improvement of survival. Various control siRNA molecules had no protective effect in vitro or in vivo.
CONCLUSIONS: RNA interference directed against the 2A protease encoding genomic region effectively confers intracellular immunity toward CVB3-mediated cell injury and improves survival, suggesting a potential role for RNA interference for future treatment options targeting enteroviral diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795330     DOI: 10.1161/01.CIR.0000160360.02040.AB

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Progress in targeted delivery of siRNA to combat Coxsackievirus.

Authors:  Anju Gautam
Journal:  Protein Cell       Date:  2011-11       Impact factor: 14.870

2.  Silencing of hepatitis A virus infection by small interfering RNAs.

Authors:  Yuri Kusov; Tatsuo Kanda; Ann Palmenberg; Jean-Yves Sgro; Verena Gauss-Müller
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Antiviral effects of small interfering RNA simultaneously inducing RNA interference and type 1 interferon in coxsackievirus myocarditis.

Authors:  Jeonghyun Ahn; Ara Ko; Eun Jung Jun; Minah Won; Yoo Kyum Kim; Eun-Seon Ju; Eun Seok Jeon; Heuiran Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

4.  Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site.

Authors:  Ji Yuan; David A Stein; Travis Lim; Dexin Qiu; Shaun Coughlin; Zhen Liu; Yinjing Wang; Robert Blouch; Hong M Moulton; Patrick L Iversen; Decheng Yang
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

5.  Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Authors:  Henry Fechner; Isaac Sipo; Dirk Westermann; Sandra Pinkert; Xiaomin Wang; Lennart Suckau; Jens Kurreck; Heinz Zeichhardt; Oliver Müller; Roland Vetter; Volker Erdmann; Carsten Tschope; Wolfgang Poller
Journal:  J Mol Med (Berl)       Date:  2008-06-12       Impact factor: 4.599

6.  Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis.

Authors:  Christine Lang; Martina Sauter; Gudrun Szalay; Giorgia Racchi; Gabriele Grassi; Giuseppe Rainaldi; Alberto Mercatanti; Florian Lang; Reinhard Kandolf; Karin Klingel
Journal:  J Mol Med (Berl)       Date:  2007-09-11       Impact factor: 4.599

Review 7.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

8.  Possibilities for RNA interference in developing hepatitis C virus therapeutics.

Authors:  Kristi L Berger; Glenn Randall
Journal:  Viruses       Date:  2010-08-06       Impact factor: 5.818

9.  Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA.

Authors:  Xin Ye; Zhen Liu; Maged Gomaa Hemida; Decheng Yang
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

10.  Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo.

Authors:  Hailan Yao; Yangde Zhang; Feng He; Caihong Wang; Zonghui Xiao; Jizhen Zou; Fang Wang; Zhewei Liu
Journal:  BMC Infect Dis       Date:  2012-08-06       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.